Abstract
Regulatory Tcells (Treg) are essential components of peripheral immune homeostasis. Adoptive Treg cell therapy has shown efficacy in a variety of immune-mediated diseases in preclinical studies and is now moving from phase I/IIa to larger phase II studies aiming to demonstrate efficacy. However, hurdles such as in vivo stability and efficacy remain to be addressed. Nevertheless, preclinical models have shown that Treg function and specificity can be increased by pharmacological substances or gene modifications, and even that conventional T cells can be converted to Treg potentially providing new sources of Treg and facilitating Treg cell therapy. The exponential growth in genetic engineering techniques and their application to T cells coupled to a large body of knowledge on Treg open numerous opportunities to generate Treg with “superpowers”. This review summarizes the genetic engineering techniques available and their applications for the next-generation of Super-Treg with increased function, stability, redirected specificity and survival.
Introduction
The immune system has developed physiological regulatory mechanisms to avoid excessive intensity or duration of immune responses and inflammation. Undesired immune reactivity needs to be controlled in pathological situations such as autoimmune diseases, solid organ transplantation (SOT), graft-vs.-host disease (GvHD), and immunogenicity of gene therapeutics and biologics. These regulatory mechanisms can be exploited therapeutically to reshape immune responses in subtler ways than conventional immunosuppressors. In fact, conventional immunosuppressors are non-selective, also inhibit protective anti-pathogen immunity and have common off-target toxicities. Although novel treatments dampen immune responses more specifically and induce immune tolerance (1, 2), alternative treatments are needed.
Among the mechanisms that maintain tolerance, both CD4+ and CD8+ FOXP3+ Treg play a central role (3–7). In addition, in both CD4+ and CD8+ compartments FOXP3− Treg are described (8). Treg are multifunctional, adaptable, living drugs, that have the potential to restore/induce durable immune tolerance and thus cure or ameliorate diseases as demonstrated in pathological rodent models (3). Although most Treg used in pre-clinical models have been polyclonal, some were antigen-specific or genetically modified (5, 6, 8–10). Small clinical studies have demonstrated the safety and some efficacy of autologous in vitro expanded polyclonal CD4+ Treg without genetic modifications in a variety of diseases (3).
Genetic modifications hold great potential to enhance their clinical efficacy as previously shown for genetically modified conventional T cells (Tconv) in the cancer field (11). The exponential development of genome engineering approaches enables strategies to generate “Super-Treg.”
This review describes genetic engineering techniques to increase the specificity, functional stability, survival, and suppressive function of Treg, as well as the generation of allogeneic off-the-shelf products, and strategies to eliminate these Super-Treg if necessary.
Genetic Engineering Tools for the Generation of Super-Treg
Targeted genetic manipulation of Treg has surged due to advances in genetic analysis and engineering (12).
Gene Transfer Using Lenti-/Retro-Viruses or Transposases
The current gold standard for the stable ectopic gene expression by T cells are replication-deficient lenti-/retro-viruses, which insert entire gene expression cassettes into the genome (13) (Figure 1). Multiple studies have demonstrated that Treg from healthy donors and autoimmune patients can be efficiently transduced in vitro (Table 1) (45). Alternatively, transposon-based gene transfer systems allow the random insertion of moderate to large cargo sizes in T cells (46, 47). Random integration of the genetic cargo and insertional mutagenesis are safety concerns requiring long-term monitoring (48), although, so far no leukemic transformation has been reported for virally transduced Tconv (49–51).
Figure 1
Table 1
| Indication | Genetic modification, technology | Results | Reference | |
|---|---|---|---|---|
| Tissues/SOT | ||||
| Partially mismatched heart transplant in mice | Murine H-2Kd-spec TCR in murine CD4+ Treg, γ−retroviral vector | Long-term survival of grafts treated with TCR transduced Treg | (14) | |
| Human skin rejection in NSG mice with human HLA-A2+ PBMCs | Human HLA-A2 CAR on human CD8+ Treg, lentiviral vector | Prevention of skin rejection, superior to polyclonal Treg | (9) | |
| Human skin xenograft transplant model | HLA-A2-specific CAR on human CD4+ Treg, lentiviral vector | Diminished skin pathology, superior to polyclonal Treg | (15) | |
| Human skin (HLA-A2+) in NRG mice with human allogeneic HLA-A2− PBMCs | Human HLA-A2 CAR CD4+ Treg, γ−retroviral vector | Prevention of skin rejection, superior to polyclonal Treg | (16) | |
| Allogeneic islet rejection in mice | Mouse Treg expressing anti-FITC MAbCAR, lentiviral vector | Incubation of Mab CAR Treg with FITC-labeled mAbs directed against islet antigens prevented islet rejection and generated tolerance | (17) | |
| Human skin xenograft model in mice | Human CD4+ Treg, lentiviral vector | CD28 but not 4-1BB co-stimulation increases Treg function | (18) | |
| GvHD/HSCT | ||||
| Xenogeneic GvHD in NSG mice (also in IPEX patient T cells) | Overexpression of FOXP3 from endogenous loci, HDR of a strong promoter using TALENs and AAV as donors | GvHD suppression | (19) | |
| Xenogeneic GvHD in NSG mice caused by human HLA-A2+ T cells | Overexpression in human CD4+ and CD8+ Tconv of FOXP3 with or without HELIOS, γ−retroviral vectors | GvHD is suppressed, CD4+/CD8+ T cells expressing FOXP3 and HELIOS more suppressive than each gene alone | (20) | |
| Xenogeneic GvHD in NSG mice caused by human HLA-A2+ T cells | 10 different 2nd generation HLA-A2 CARs human Treg, lentiviral vector with NGFR | CD28wt A2-CAR provide superior effects; TNFR A2-CARs decrease survival vs. negative control | (21) | |
| Xenogeneic GvHD in NSG mice caused by human HLA-A2+ T cells | Human HLA-A2 CAR CD8+ Treg, lentiviral vector | GvHD is suppressed | (9) | |
| Xenogeneic GvHD in NSG mice caused by human HLA-A2+ T cells | Human HLA-A2 CAR CD4+ Treg, lentiviral vector | Prevented GvHD | (10) | |
| Allogeneic acute GvHD in mice | Mouse CD4+CD25− T cells overexpressing Foxp3, lentiviral vector | Prevented GvHD, preserved GVL | (22) | |
| Inherited genetic diseases | ||||
| HLA-transgenic, FVIII-deficient mouse model (hemophilia A) | FVIII-specific TCR in human CD4+ Treg, γ−retroviral vector | Inhibits factor VIII-specific antibody production | (23) | |
| FVIII-deficient mouse model | FVIII-specific human CAR in human CD4+ Treg, γ−retroviral vector | Suppressed recall antibody response | (24) | |
| FVIII-deficient mouse model | Foxp3 expressed by mouse T anti-human FVIII cells, γ−retroviral vector | Inhibits factor VIII-specific antibody production | (25) | |
| IPEX | Human FOXP3 gene in CD4+ Tconv cells, lentiviral vector | Conversion into functional Treg, especially with naïve T cells | (26) | |
| T cells and HSPCs | Introduction of FOXP3 cDNA by HDR via CRISPR/Cas9 RNP and recombinant adeno-associated viral serotype 6 + NGFR tag in human Tconv, HSPCs and Treg as well as patient cells | Endogenous locus gene insertion restores physiological regulation in Tconv; also T cell repopulation in humanized mice with-corrected HSPCs | (27) | |
| Allergy/hypersensitivity | ||||
| OVA-induced and passive anaphylaxis in mice | OVA-fused to antigen receptor signaling domains in murine and human CD4+ Treg | Autoantibody producing B are suppressed by BAR Treg, protects from hypothermia if given before OVA challenge | (28) | |
| Autoimmunity | IBD | |||
| Tconv cell transfer | Overexpression of Foxp3, γ−retroviral vector | Control of intestinal inflammation | (29) | |
| Trinitrobenzenesulphoric acid colitis in mice | 2,4,6-trinitrophenol-specific murine CAR in CD4+ Treg, γ−retroviral vector | Reduces acute colitis | (30) | |
| T cell-transfer colitis and azoxymethane–dextran sodium sulfate model for colitis-associated colorectal cancer | Carcinoembryonic antigen CAR in mouse CD4+ Treg, γ−retroviral vectors | Reduces acute colitis in both models and reduction in colon cancer | (31) | |
| Colitis induced by naïve T cells injected in Rag2−/− mice | TET1-CD overexpression in murine CD4+ Treg, γ−retroviral vector | Reduced weight loss | (32) | |
| Type 1 diabetes | ||||
| NOD mice | Foxp3 overexpression in CD4+ Tconv with or without islet specificites, γ−retroviral vector | Only with antigen-specific CD4 cells but not polyclonal CD4+ FOXP3+ controlled recent onset diabetes despite similar suppression in vitro | (33) | |
| NOD mice | Murine CD3ζ/CD28 human insulin-specific CAR and Foxp3 (proteolytic cleavage) + CD90.1 with IRES in naïve CD4+ effector T cells, γ-retroviral vector | Despite effector origin behavior and nTreg like phenotype, unable to prevent diabetes, but survive 17 weeks | (34) | |
| Neurological | ||||
| Experimental autoimmune encephalitis induced by MOG, intranasal Treg delivery | CAR anti-MOG- + murine Foxp3 sequences in CD4+ T cells, lentiviral vector | Reduces symptoms, cytokine release; induce resistance to MOG re-challenge | (35) | |
| Experimental autoimmune encephalitis | MOG or MOG/NF-M bi-specific TCR- murine CD4+ Treg, γ−retroviral vector | Superiority of bi-specific Treg even if disease initiating antigen is not directly targeted | (36) | |
| Experimental autoimmune encephalitis in DR15 transgenic mice induced by MOG | Myelin-basic protein specific TCR transgenic human CD4+ Treg γ−retroviral vector | Alleviation of symptoms | (37) | |
| Rheumatological | ||||
| Collagen-induced arthritis | TCR from CD4+ cells involved in arthritis expressed in Tconv in association with Foxp3 and TNFR-Ig, γ−retroviral vectors | Inhibition of disease and of inflammatory cytokines | (38) | |
| Collagen-induced arthritis | Tamoxifen-inducible or constitutive ectopic FOXP3 expression, γ−retroviral vectors | Only inducible FOXP3 expression inhibited the disease due to Treg migration to lymph nodes | (39) | |
| Arthritis mouse model (immunization with OVA followed by intra-articular rechallenge) | Murine OTII TCR Foxp3, γ−retroviral vector | Prevent symptoms when rechallenge combined with OVA | (40) | |
| Humanized mice (HLA-DR1 transgenic), arthritis induced with bovine collagen II + adjuvant | Foxp3 + HLA-DR1 covalently linked to type II collagen antigen in murine naïve T cells, retroviral vector | Inhibition of disease development and reduction of autoimmune effector T cells | (41) | |
| Lupus mouse model | Tconv expressing anti-CD19 CARs | B cells are killed, reduction in kidney lupus lesions | (42) | |
| Skin | ||||
| Contact hypersensitivity and autoimmune dermatitis | CD4+ Tconv with ectopic expression of Foxp3, γ−retroviral vector | Reduced skin lesions, homing of Treg to skin and lymph nodes | (43) | |
| Pemphigus mouse model | CD4+ Tconv expressing an autoantigen in a chimeric autoantibody receptor (called CAAR) are recognized by autoreactive desmoglein-3 B cells, lentiviral vector | Autoreactive desmoglein-3 B cells are killed by CAAR Tconv, reduction of pemphigus lesions | (44) | |
T cell products modified in vitro to treat immune-mediated disease models in vivo or cells from human patients with genetic diseases1.
1Only T cells genetically modified in vitro, Treg derived from KO or KI mice are excluded from this table but mentioned in the text.
HSPC, hematopoietic stem progenitor cells; NF-M, neurofilament-medium.
Gene Editing With Programmable Nuclease Systems
Zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) enable recognition of a genetic sequence through protein/DNA binding and induce double-strand DNA breaks (DSBs) via dimerization (74–76) (Figure 1). However, the discovery of the CRISPR-Cas system has induced a paradigm shift as it enables easier design of efficient nucleases. Recently, highly efficient optimized Cas9 nuclease variants have been developed (77–79). DSBs at specific sequences are repaired by non-homologous end joining or homology directed repair (HDR) (by providing a DNA repair template) to achieve gene KO or targeted mutation/insertion respectively (Figure 1). This was successfully applied to sorted human Treg in the correction of a pathogenic IL-2Ra in approximately 20% and GFP insertions in up to 40% of CD4+ Treg (80). Targeting multiple genomic loci with site-specific nucleases allows multiplexing of gene knockouts (KOs) in a single intervention. Two recent manuscripts described CRISPR/Cas9 KO screening in Tregs to define genes involved in mouse Treg stability and function (63, 81).
Nucleases without active nuclease domains can be repurposed to shuttle other bioactive cargo to introduce small base changes, modify epigenetic marks or interfere with transcription (82). Nuclease-deficient Cas9 (dCas9) fused to enzymes with different functions, can be used to specifically edit certain bases (83) (Figure 1). Use of base editor proteins for gene multiplexing was successfully achieved with very high efficiency in Tconv (84). Potentially, the newly introduced prime gene editing system could also be applied to insert or replace small gene sequences efficiently without the need for DNA DSBs (85).
Delivery of Gene Editing Components Into Cells
Gene editing requires efficient delivery of the respective components into the cells’ nuclei. Gene editing enzymes can be transferred as plasmid, mRNA, or recombinant protein-RNA complexes (RNP). HDR repair templates are required as single- or double-stranded DNA. Electroporation allows the highly efficient transfection of protein, mRNA, or plasmids into T cells. Viral vectors exploit their tropism to deliver their cargo with more control than blunt electroshocks. Adenovirus-associated virus (AAV) serotype 6 has been prominently used to deliver genetic cargo into human Tconv and immunopathology-polyendocrinopathy-enteropathy-X-linked (IPEX) syndrome-patient-derived Tconv to induce Treg (27, 86). Lentiviruses and AAVs can be modified to incorporate nuclease enzymes in their capsids to achieve all-in-one delivery solutions for CRISPR-Cas gene editing and DNA transfer tested in mice and human embryonic kidney cells or lymphoblastoid cell lines (87–90). Combination of transposon-based CAR transfer through an anti-CD3 directed nanoparticle system allowed efficient T cell reprogramming in immunocompetent mice in vivo (52).
Potential Genotoxicity of Gene Editing
Off-target effects are a concern for the clinical translation of gene editing and careful experimental design as well as thorough off-target analysis are required (91). Transient presence of the components and high-fidelity nucleases reduce the risk of off-targets. Further, unwanted repair outcomes at the edited on-target sites have been observed including large deletions and translocations (92, 93). Translocations are a particular risk when multiplexing loci in a single manipulation (94), and decrease cellular fitness after transfusion (95).
Immunogenicity of Cells After Genetic Modification
Viral vectors, nuclease systems, and newly introduced transgenes can be immunogenic, potentially decreasing the efficacy of Super-Treg and even posing a potential safety risk as previously seen using Tconv (96, 97). Of note, most human adults have pre-existing adaptive immunity toward Cas9 proteins and enriched Cas9-reactive Tconv can eliminate Cas9-expressing lymphoblastoid cell lines in vitro, which can be reduced by Cas9-specific Treg (98). However, T cells edited using Cas9 delivered by RNP electroporation did not elicit an immune response and persisted, which might be due to the low abundance of Cas9 in the edited final product or defective immune responses in the patients (95).
For TALENs and ZFNs, despite being immunogenic per se, stemming from Xanthomonas, which infects plants, and partially from Flavobacterium okeanokoites, which was isolated from the seabed, there is a low risk for previous exposure to the enzymes. In contrast, Cas9 stems from Streptococcus pyogenes, which is a common human pathogen. However, development of an immune response upon permanent expression may still be relevant.
Genetic Engineering Strategies for Enhanced Stability and Function of Treg
A limitation of adoptive Treg therapy is that inflammatory conditions can inhibit their function or even switch them to Tconv (99, 100). Therefore, the identification of pathways regulating Treg function and stability are key to define targets for genetically engineering more stable and robust Treg (Figure 2).
Figure 2
FOXP3
Given the key role of FOXP3 to control Treg function and that its expression and function are labile or even lost in patients with mutations in the FOXP3 gene (IPEX), numerous studies have analyzed how to increase or stabilize its expression. Functional CD4+ Treg from IPEX patients could be obtained by ectopic expression of FOXP3 in their Tconv (26), but also with more clinical potential by precise HDR on hematopoietic stem cells (27) (Table 1).
This strategy could also allow high numbers of Treg to be obtained from Tconv. In CD4+ Tconv, ectopic expression of FOXP3 using retroviral vectors (22, 26, 43) or by HDR of a strong promoter upstream of the FOXP3 coding sequences (19) allowed generation of Treg that suppressed CD4+ Tconv not only in vitro but also inhibited GvHD, colitis or dermatitis in animal models (Table 1). Interestingly, tamoxifen-induced but not constitutive FOXP3 expression in CD4+ Tconv resulted in control of autoimmune arthritis by migration into lymph nodes (39). In line with these results, control of type 1 diabetes (T1D) was obtained only with islet-specific CD4+ Tconv homing to lymph nodes and not with polyclonal CD4+ FOXP3-expressing Tconv in a mouse model (33). Transduction of mouse anti-human FVIII T cells with Foxp3 resulted in decrease anti-FVIII antibodies in hemophilia A mice (25). In in vitro studies, human pathogenic synovial Tconv from rheumatoid arthritis patients ectopically expressing FOXP3 showed reduced Tconv responses (101). Other publications with in vitro studies described that ectopic expression of one (102) or both (103) isoforms of FOXP3 in CD4+ Tconv resulted in functional human Treg. Overexpression of the transcription factor HELIOS cooperates with FOXP3 to generate both CD4+ and CD8+ Treg from human Tconv, but particularly CD8+ T cells (20). Similarly, delivery of dCas9 fused to a transcriptional activator and guides recognizing FOXP3 promoter sequences increases FOXP3 expression (104).
Epigenetic regulation of FOXP3 expression is important for the expression of FOXP3 in Treg. Demethylation of CpG dinucleotides at the FOXP3 locus including at regulatory elements in the intronic region, at the proximal promotor and the upstream enhancer stabilizes FOXP3 expression (59, 105, 106). If these Treg-specific demethylated regions (TSDR) are not fully demethylated, such as in the induction of FOXP3 expression by TGF-β, FOXP3 expression can be lost upon restimulation in mouse Treg (107). Epigenetic modifications of FOXP3 for TSDR demethylation in Treg by azacytidine (a DNA methyltransferase inhibitor) induces and stabilizes FOXP3 expression in mouse Treg (107). Partial demethylation of TSDR CNS2 in Treg by catalytically inactive CRISPR-Cas9 (dCas9) fused to the catalytic domain of ten-eleven translocation (TET) protein, which promotes demethylation, resulted in stable FOXP3 expression and increased suppressive activity in vivo in mice (32). However, a similar system using dCas9 fused to TET1 did not increase FOXP3 levels in mouse Treg (108).
Transcription of FOXP3 can be repressed by histone deacetylation in the FOXP3 promoter by histone deacetylase 7 (HDAC7), and HDAC inhibitors increase FOXP3 expression through regulation of both the gene and the protein, and can improve the suppressive action of murine and human Treg (109, 110). A dCas9 fused to the catalytic domain of histone acetyltransferase (HAT) p300 showed that histone acetylation targeted to the promoter locus was able to activate and stabilize FOXP3 levels in mice, even under inflammatory conditions (108).
Lysine acetylation by HATs of both histones in the FOXP3 locus and of FOXP3 itself increases its transcription and reduces its poly-ubiquitination and degradation as well as enhancing FOXP3 chromatin binding in mouse and human Treg (111, 112). Hyperacetylation by HDAC inhibitors or overexpression of HATs can increase FOXP3 levels in mouse and human Treg (112, 113). For example, P300 and CBP HATs acetylate FOXP3, increasing its DNA binding and thereby regulating murine Treg function and stability (60). CBP and P300 affect Treg development through several mechanisms, including promoting FOXP3 production, and by participating in a positive feedback loop that enhances murine Treg stability in inflammatory environments, which could be further exploited through molecular engineering (60).
Ubiquitination of both histones at the FOXP3 locus and of the protein itself is important in the regulation of FOXP3, via members of the deubiquitination module of the SAGA complex, Usp22, and Atxn7l3. Loss of Usp22 in Treg reduces Foxp3 transcript levels, increases FOXP3 ubiquitination and degradation, and reduces suppressive activity in vivo in mice (63, 81). Furthermore, Stub1 (114) and TRAF6 (115) E3 ubiquitin ligases induced by inflammation target the ubiquitination of FOXP3 followed by its degradation in mouse and human Treg and represent interesting targets for genetic ablation in Treg products. In contrast, Hrd1, an E3 ligase critical in suppressing the ER stress response, stabilizes murine FOXP3 expression (116). In terms of kinases and phosphorylation of FOXP3, PIM1 (117), and CDK2 (118) kinases negatively regulate FOXP3 and Treg function.
Other Transcription Factors
HIF‐1α reacts to hypoxia by triggering the switch between mitochondrial oxidative phosphorylation and aerobic glycolysis (119), and is also induced by continuous TCR stimulation via mTOR in human T cells (120). In mouse Treg and human embryonic kidney cells, HIF-1α promotes the ubiquitination and proteasomal degradation of FOXP3 (65), and its upregulation in response to hypoxia inhibits FOXP3 expression in mouse T cells (121). HIF-1α also inhibits the development of mouse Treg through increasing glycolysis by upregulating glycolytic proteins (122). HIF-1α deficiency inhibits glycolysis and therefore promotes the differentiation of murine Treg over Th17 cells (123). Deletion of HIF-1α in mice increases FOXP3 expression, and reduces transcription of Th17 cell-related genes (65, 121), suggesting HIF-1α KO as a means to improve Treg stability through metabolic control. Differentiation of induced human Treg is inhibited by IL-1β in a HIF-1α-dependent manner (124). However, in human Jurkat cells, HIF-1α induction increased FOXP3 protein and mRNA levels, which was reversed by knockdown of HIF1α (125, 126). On the same lines, exposure of human PBMCs to hypoxia increased the proportions of FOXP3+ Treg among CD4+ CD25+ T cells and their suppressive potential to inhibit Tconv proliferation, which was also observed in mouse splenocytes (125).
Aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor that functions as an environmental sensor and mediates the differentiation of both Th17 cells and FOXP3+ Treg. AHR is highly expressed in peripheral Treg in the gut, and its deletion impairs their function. Conversely, activation of AHR in transgenic mice increases the population and migration of Treg (127). AHR inhibited proinflammatory cytokines (IFNγ and IL-17) and Th1-associated genes, but was dispensable for FOXP3 stability. Ahr activation in a conditional knock-in in Treg in a mouse model of colitis enhances suppressive activity and migration to the inflammatory site, and a reduction in proinflammatory T cells (127). Furthermore, AHR activation was found to promote generation of human induced Treg, producing IL-10 and controlling Tconv via granzyme B, but did not have an effect on thymic-derived human Treg (128, 129).
Pro-Inflammatory Cytokines and Extracellular Metabolites
IL-6 is a proinflammatory cytokine that induces the expression of kinase PIM1 during inflammation, which inhibits expression of Treg markers including CTLA4 and CD25 via phosphorylation of FOXP3 (130). T cell-specific deletion of the IL-6 receptor gp130 in mice reduces IL-6 signaling and promotes the conversion of peripheral Tconv into Treg (131). IL-6 blockade suppresses the immune response in models of autoimmune disease and is used in the treatment of rheumatoid arthritis (132, 133). At the same time, a recent publication showed that IL-6Rα-deficient Treg lost suppression and aggravated experimental glomerulonephritis (134). Therefore, mitigating IL-6 signaling in Treg, which was assumed to be a compelling strategy to enhance their functionality in inflamed tissues and in the presence of high levels of IL-6 needs more investigation and has to be overthought critically.
The purinergic receptor P2X7 induces T cell activation through binding of ATP, pushing the balance toward proinflammatory Th17 cells, and decreasing the viability and suppressive function of mouse Treg (135). In a mouse model of experimental colitis, P2X7 receptor KO resulted in an increase of activated Treg, IL-10, and TGF-β (136). Preventing P2X7 signaling is able to preserve mouse Treg stability by stabilization of nuclear complexes of NFAT and FOXP3, and the resulting downstream transcription of Treg-linked genes (135). CD39 and CD73 expressed by Treg degrade ATP to adenosine and adenosine itself can enhance the expansion and immunosuppressive function of human Treg in vitro by binding to the purinergic P1 adenosine 2A receptor (A2AR) (137, 138). Thus, genetic overexpression of CD39 could be beneficial.
Although Treg produce immunosuppressive cytokines, such as IL-10 (139), TGFβ (140), IL-34 (141, 142), IL-35 (143), and FGL2 (144, 145), their production could be increased by genetic means.
Treg with increased function and stability could therefore be engineered by inhibition of negative regulatory genes (using nucleases), overexpression of positive regulators (using lentiviral vectors), likely giving more precise control than small molecule treatments which may bind multiple members of a family (for example acetylases).
Genetic Engineering Strategies for Increased Proliferation and Engraftment of Treg
Proliferation Signals
Survival of human naïve CD4+ Treg is mediated by IL-7 signaling, which increases anti-apoptotic BCL-2 (146) while long-term survival of CD4+ Treg is dependent on IL-2 (147) and of CD8+ Treg on IL-15 (4). Low dose IL-2 infusion was shown to increase Treg numbers, FOXP3 expression and lead to a more diverse repertoire of CD4+ and CD8+ Treg in patients (4, 148). Currently, there are different engineered IL-2–based drugs targeting CD25 on Treg, also referred to as IL-2 muteins (149) in clinical trials. Since IL-2 signaling is associated with long-term survival of human Treg, constitutively active STAT5 (150), which is an important signal transducer in this pathway, may improve Treg survival and abolish their dependence on extracellular IL-2 (Figure 2). Moreover, to make Treg independent of exogenous IL-2 that may activate Tconv and NK-cells, they could be armed with their own IL-2 for self-supply. However, ectopic IL-2 expression could compromise the immunosuppressive mechanism of IL-2 deprivation of surrounding Tconv. A mutated IL-2R that only binds an IL-2 mutein and not wild-type IL-2 could be engineered in mouse Treg that are then selectively expanded (151).
A strategy to engineer constitutively active cytokine receptors independent of cytokine availability may also be translated from Tconv to Treg (152), e.g., allowing long-term survival via a constitutively active IL-2 receptor (147). Moreover, chimeric cytokine receptors (CARs) converting pro-inflammatory signals (captured by the extracellular domain of the respective receptor, e.g., IL-6) into Treg-survival signals using the intracellular signal transduction domains (e.g., IL-2 receptor) of pro-survival signals may contribute to improved survival of Treg products as reported previously in a mirroring approach for the support of Tconv (153).
Apoptotic Mechanisms
Several pathways inducing Treg apoptosis seem to be dependent on FAS (154, 155) and pro-survival pathways on BCL-2 (73, 146, 154). Thus, disruption of FAS or over-expression of BCL-2 may significantly increase the viability of Treg. An alternative may be to increase the PD1-PDL1 signaling in Treg, since PD1 blockade was reported to lead to downregulation of BCL-2 and increased FAS receptor expression (154). However, mouse Treg lacking PD-1 were shown to be activated and have high suppressive potential (156), which underlines the necessity for further studies of this axis in human Treg. Additionally, human CD4+ Treg express PD-L1 in response to IL-7 (154) and induce apoptosis in PD-1+ Tconv (157) and autoreactive B-cells (158). As CTLA-4 has an important role in Treg function and increased degradation of CTLA-4 as present in LRBA deficiency is associated with high levels of Treg apoptosis, stabilizing strategies for sustained or increased CTLA-4 expression may also improve human Treg survival (159, 160).
Metabolism
Treg and Tconv have different metabolic requirements, as Treg use glycolysis and increase fatty acid oxidation upon activation (161, 162). Acetyl CoA carboxylase (ACC) regulates both biosynthesis and breakdown of long chain fatty acids and ACC1 deficiency induces high levels of FOXP3 expression in mouse and human Treg (163). Therefore, ACC is a potential target for altering the metabolic programming of T cells, as blocking fatty acid synthesis favors Treg induction and prevents Th17 development. Liver kinase 1 (LKB1), a metabolic sensor, is essential for murine Treg stability and suppressive activity by inhibiting expression of pro-inflammatory cytokines and preventing exhaustion (164). LKB1 and its target genes are downregulated in impaired Treg from patients with acute GvHD and Lkb1 deletion in Treg in mice leads to severe autoimmune inflammation, and can aggravate acute GvHD (164, 165). LKB1 also stabilizes FOXP3 expression in Treg and expression levels correlate with Foxp3 expression in human Treg (165). In contrast to Tconv, murine and human Treg do not accumulate lactate and are insensitive to lactate in medium (166). LKB1 increases glycolysis and lactate formation and in mice, abrogation of Lkb1 leads to loss of mitochondrial integrity and to a dramatic reduction of Treg (167). Thus, LKB1 overexpression could be used to stabilize FOXP3 expression, maintain metabolic homeostasis, and avoid exhaustion in Treg.
Drug Resistances
In several settings, Treg are infused into patients treated with immunosuppressants to inhibit Tconv but also compromise Treg function (168). Hence, making Treg resistant to these drugs may allow their preferential survival. Indeed, strategies aiming to make antiviral T cells resistant to calcineurin inhibitors or glucocorticoids including knockdown (169), knockout (170–172) or introduction of calcineurin-resistant mutants (173), might also be applied to Treg.
Genetic Engineering Strategies for Redirecting Treg Antigen Specificity
Treg-mediated tolerance can be improved by increasing antigen specificity and with the development of gene editing, redirection of Treg specificity became feasible (Figure 2). Indeed, antigen-specific Treg have an increased suppressive ability and a stronger efficacy in the regulation of the immune response and an improved migration to the site of interest compared to polyclonal Treg (9, 10, 174–178). While ex vivo expansion in presence of the antigen of interest, or in vivo by administration of peptides recognized only by Treg (176, 177, 179) is possible, using genome editing would be advantageous as it would confer antigen-specificity to a larger Treg population rather than amplifying a very small subset of antigen-specific Treg, which can be challenging. However, genome editing to redirect specificity would also multiply the danger of contaminating Tconv that may have a proliferative advantage in cytokine-rich medium used during Treg expansion and could overgrow the culture, multiplying their abundance in the final product. Thus, a very pure starting population is required or the undesired cells (such as CD8+ non-Treg) must be depleted at a later time point. However, the latter is challenging for, e.g., CD4+ Tconv, which are not easily distinguishable from Treg after culture, but could also cause detrimental effects. Furthermore, it will be crucial to choose a receptor with appropriate affinity for Treg to exclude the possibility of instabilities. Even pre-selection of more stable Treg subsets or genetic engineering to make them more stable may be required to generate a safe product.
Treg specificity can be redirected by the use of TCRs and CARs (180, 181). Importantly, Treg with a single specificity have been shown to suppress multiple antigens if presented by an APC simultaneously, as shown in autoimmune, GVHD, and SOT models (9, 10, 15, 182).
TCRs
Redirecting T cell specificity with an engineered TCR was reported as early as 1996 using a chimeric TCRβ chain consisting of a single-chain Fv portion derived from a monoclonal antibody paired with endogenous TCR/CD3 component, thus providing antibody and TCR specificity (183). The use of TCRs has several advantages since it represents a physiological way of activating T cells and allows the targeting of intracellular antigens presented by HLA molecules. In addition, expression of only one antigen per cell is sufficient to activate the TCR-expressing Treg. However, HLA restriction limits coverage to a particular part of the population. Careful identification of a high affinity TCR-α/β is required to ensure that they retain functionality without acquiring a harmful unpredicted specificity when mispaired with the endogenous TCR. To avoid this, disruption of the endogenous TCR using nucleases might be necessary (184). Proofs of concept include human Treg expressing a myelin basic protein-specific TCR derived from a multiple sclerosis patient, which showed in vitro and in vivo efficacy in an EAE model (37). Efficacy was also demonstrated in a mouse model of hemophilia A using human Treg engineered with a factor-VIII-specific TCR isolated from an hemophilia A patient (23). TCRs against autoantigens have also shown in vivo efficacy in models of arthritis (38) (Table 1) or in vitro recognizing islet antigens involved in T1D (182, 185).
Interestingly, MHC-I-restricted TCRs have been shown to be functional in human CD4+ Treg, bypassing the need for the CD8 coreceptor, and this was the case for TCRs with low affinity not functional on CD4+ Tconv (186).
A potential future perspective of these studies is the use of TCRs isolated from Treg and not from effector T cells as done until now. Although only very few TCRs and the peptides recognized by Treg TCRs have been identified until now, they do show differences with TCRs from Tconv, e.g., recognizing longer (15aa) peptides or reversed TCR docking modes (176, 177, 187).
CARs
Pioneer work by Eshar and colleagues in the autoimmune field allowed the generation of CARs in which antigen recognition signaling domains of antibodies and a TCR-zeta-chain were fused in a single molecule (181). Sequences from co-stimulatory proteins were also fused in cis and the most commonly used ones are the intracellular portions of CD28 or 4-1BB. While the 4-1BB signaling domain used in the CAR construct has been suggested to enhance Tconv persistence and improve the toxicity profile in patients, CD28 was shown to be more beneficial for Treg phenotype and function (18). CAR technology has some advantages over TCRs, the most important one being the absence of HLA restriction. CAR-Treg are less dependent on IL-2 compared to TCR-expressing Treg, potentially due to costimulatory signals received upon activation of the CAR. However, CARs also have several limitations vs. TCRs, as CARs only recognize extracellular antigens. Additionally, CARs require higher expression levels than TCRs (100–10,000 antigens/cell vs. <10, respectively) for sufficient activation although increasing the affinity of CARs can also increase efficacy (188, 189). CAR molecules can be immunogenic, not only due to murine scFv fragments, but also due to the generation of new epitopes in a chimeric molecule, and this impacts the persistence of effector T cells in patients (97, 190). Even induction of anti-CAR antibodies was described for effector T cells and the immune reaction was reported to be able to cause anaphylaxis in a patient repetitively treated with CAR T cells (191). Possibly, anti-CAR immune responses may be less severe if the CAR is expressed in an immunosuppressive Treg compared to expression in pro-inflammatory Tconv.
Human CD4+ and CD8+ CAR-Treg have been used in mouse models of FVIII hemophilia, SOT and GVHD as well as in vitro with CD4+ Treg from IPEX patients (for a complete list see Table 1). Mouse CD4+ CAR-Treg have demonstrated efficacy in mouse models of SOT, GvHD, IPEX, colitis, allergic asthma, rheumatological diseases, and EAE (Table 1).
The importance of internal vs. external antigen targets could orientate toward the generation of a TCR- vs. a CAR-transgenic Treg. There are also new tools developed such as CAR-T cells possessing a TCR-like antibody moiety (TCR-like CAR-T) with a single-chain variable domain specific for a distinct peptide/MHC (192). In an original approach, CD4+ Treg expressing a CAR directed against FITC and ex vivo incubated with FITC-labeled antibodies directed against donor alloantigens inhibited pancreatic islet rejection (17). Similarly, the UniCAR system, in which a universal CAR is indirectly linked to their target cells via a separate targeting module, has been applied to human Treg (193). In a new approach to treat autoantibody-driven diseases, CD4+ Treg have been engineered to express CARs with antigens recognized by B-cells (called BARs, where the scFv fragment is replaced by an antigen) (28). Similarly, Tconv expressing an autoantigen in a chimeric autoantibody receptor (CAAR) mediated killing of the autoreactive B-cells, as shown in pemphigus (44). Also, Tconv expressing anti-CD19 CARs generally used to treat B-cell malignancies were used to treat mice with lupus disease (42) (Table 1).
Genetic Engineering Strategies for the Use of Off-the-Shelf Allogeneic Treg
Genetic engineering of allogeneic Treg as an off-the-shelf product would allow cells from a given donor to treat several patients thereby reducing the cost per dose as well as increasing treatment flexibility (Figure 2). Nevertheless, this approach has the draw-back of allogenicity due to recognition of foreign MHC-I and -II antigens by host T cells. To extend allo-Treg persistence, deletion of β-2 microglobulin and CIITA could be performed to eliminate MHC-I and -II antigens, respectively. Although absence of MHC-I may increase the susceptibility of Treg to NK cell lysis and that could limit therapeutic efficacy, activated Treg may be more resistant in vivo and indeed triple-KO T cells have been found to persist better than HLA-sufficient T cells. In addition, overexpression of HLA-E or CD47, important in NK cell inhibition through inhibitory receptors, could prevent NK cell-mediated lysis (194–196). Preventing an immune response against allogeneic cells is even more important in the Treg setting than in the Tconv setting, as here any pro-inflammatory immune response can be detrimental as opposed to the Tconv setting, in which the goal is to create a pro-inflammatory environment. However, it has also to be considered that Treg have anti-inflammatory properties per se and first applications of 3rd party-derived Treg after umbilical cord stem cell transplantations did not reveal relevant adverse events (197).
Another potential risk using allogeneic T cells is GvHD although the inherent suppressive function of Treg makes this risk less relevant than with allogeneic Tconv. Generating highly specific, allogeneic Treg products also harbors the risk of toxicity in the case of unstable Treg or contaminating Tconv. Strategies such as suicide genes and elimination markers—some already clinically evaluated in Tconv—could be included to shut off adoptively transferred “stealth” Treg in case of toxicity (198) (Figure 2).
Pluripotent stem cells-derived Tconv mainly for cancer use have been described (199, 200) and derivation of Treg would be an important step not only to have an unlimited source of cells but also for generating “stealth” Treg.
It will also be important to better understand the migration of Treg to different anatomical compartments and their survival. To date, Treg infused in patients have only been identified in vivo in T1D patients after labeling CD4+ Treg with deuterium but this strategy is limited to cells in circulation and not in tissues (201). Also, mouse CD4+ Treg have been transduced for the expression of the sodium-iodide symporter (NIS). NIS uptakes into only living cells plasma iodide and other substrates detected using PET or SPECT/CT. NIS-expressing Treg radiolabeled with Technetium-99m pertechnetate were detected in spleen with no effects on cell viability, phenotype, and function (202).
Gmp Compliant Manufacturing and Clinical Perspectives of Super-Treg
An increasing number of clinical trials employing adoptive Treg transfer are currently ongoing or registered addressing a large variety of applications (3, 5, 6). The generation of Super-Treg with genetic modifications will require the use of improved protocols for the purification and amplification of Treg to prevent contaminating Tconv with putative hazard. Bead-based or flow cytometry-based cell sorters (9, 14–16, 18), either fully closed or open systems, allow for clinical grade CD4+ Treg isolation. For clinical-grade CD8+ Treg isolation flow cytometry-based approaches are used. Typically, in vitro Treg expansion before adoptive transfer takes around 2–3 weeks (9, 14).
Release criteria usually include the classical phenotypic Super-Treg markers (e.g., CD25, FOXP3 for CD4+ Treg) and absence of pro-inflammatory markers, e.g., pro-inflammatory cytokine production and CD45RC for CD8+ Treg. Functional assays or epigenetic assays may be beneficial, however cannot be realized in a timely manner before Treg product infusion.
Super-Treg quality control will require additional control of nuclease delivery and duration of expression as well as maximization of efficacy preferentially using vector-free systems (41). Safety controls will include in silico as well as in vitro analysis of off-target effects of nucleases and careful analysis of the edited loci (41). In this context, a clinical trial using CRISPR/Cas9-genetically modified in cancer patients has been recently published (95).
A Phase I/II clinical trial is approved in UK that plans to apply CAR anti-HLA-A2 CD4+ Treg in kidney transplantation. Academic multi-center consortia (like the ReSHAPE consortium, http://www.reshape-h2020.eu/partnership) aim to generate CD4+ and CD8+ Super-Treg and to apply them to both animal models of immune-mediated disease and clinically in kidney transplanted patients.
Discussion
The specific challenge of using Treg therapy in general in human pathologies will be to interfere with established autoimmunity, rather than de novo immunizations (SOT, GvHD, gene therapies, biologics), without provoking global immunosuppression.
A future direction is the use of CARs recognizing inflamed or damaged tissues that could direct the Treg to these pathological areas, as shown by preliminary data (203).
The demonstration that Treg can stimulate tissue regeneration (204–208) reveals regenerative medicine as a novel indication for Super-Treg.
As for CAR-Tconv (209), the simultaneous use of both CD4+ and CD8+ CAR-Treg may prove to be superior to each subset alone.
Treg will likely be modified using new T cell engineering strategies, such as synthetic Notch receptors that have an extracellular single-chain antibody and intracellular transcriptional domains that are released and activate expression of target genes (210).
Immune humanized immunodeficient animal models will continue to be useful to address many questions in preclinical studies (211). Moreover, human and/or patient organoids, may gain more importance and are promising candidates for examining Treg function in disease models (212).
Biomarker studies will be important to define not only the effects of Super-Treg therapy but also the timing and doses of their administration.
The knowledge of Treg biology, their success in animal models and early clinical trials as well as the explosion of genome editing techniques are synergistic approaches to treat immune-mediated diseases in the future.
Funding
This work was funded by the ReSHAPE project from the European Union's Horizion 2020 research and innovation programme under grant agreement No 825392. It was also realized in the context and partially funded by the Labex IGO program supported by the National Research Agency via the investment of the future program ANR-11-LABX-0016-01, and a Berlin Institute of Health (BIH) crossfield grant “regulatory T cells.”
Statements
Author contributions
DW, JG, LA, SB, CG, and IA performed bibliography searches and wrote and edited the manuscript. MS-H, H-DV, and PR edited the manuscript. DW generated Figure 1. SB generated Figure 2. LA generated Table 1. IA planned the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of interest
CG, IA, and SB have patents that have been licensed to TxCell S.A., a Sangamo Company. DW, LA, PR, H-DV, and MS-H have filed patent applications on Treg-related diagnostics and therapeutics. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
PicardaEBézieSBoucaultLAutrusseauEKilensSMeistermannDet al. Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells. JCI Insight (2017) 92(3):e90088. doi: 10.1172/jci.insight.90088
2
HeroldKCBundyBNLongSABluestoneJADiMeglioLADufortMJet al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med (2019) 381(7):603–13. doi: 10.1056/NEJMoa1902226
3
SharabiATsokosMGDingYMalekTRKlatzmannDTsokosGC. Regulatory T cells in the treatment of disease. Nat Rev Drug Discovery (2018) 17(11):823–44. doi: 10.1038/nrd.2018.148
4
FlippeLBézieSAnegonIGuillonneauC. Future prospects for CD8+ regulatory T cells in immune tolerance. Immunological Rev (2019) 292(1):209–24. Oct 8 [cited 2019 Nov 6]; Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/imr.12812. doi: 10.1111/imr.12812
5
RomanoMFanelliGAlbanyCJGigantiGLombardiG. Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity. Front Immunol (2019) 10:43. doi: 10.3389/fimmu.2019.00043
6
FerreiraLMRMullerYDBluestoneJATangQ. Next-generation regulatory T cell therapy. Nat Rev Drug Discovery (2019) 18(10):749–69. doi: 10.1038/s41573-019-0041-4
7
LeesJR. CD8+ T cells: The past and future of immune regulation. Cell Immunol (2020) 357:104212. doi: 10.1016/j.cellimm.2020.104212
8
GregoriSRoncaroloMG. Engineered T Regulatory Type 1 Cells for Clinical Application. Front Immunol (2018) 9:233. doi: 10.3389/fimmu.2018.00233
9
BezieSCharreauBVimondNLasselinJGerardNNerriere-DaguinVet al. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice. Blood Adv (2019) 3(22):3522–38. doi: 10.1182/bloodadvances.2019000411
10
MacDonaldKGHoeppliREHuangQGilliesJLucianiDSOrbanPCet al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest (2016) 126(4):1413–24. doi: 10.1172/JCI82771
11
JuneCHSadelainM. Chimeric Antigen Receptor Therapy. N Engl J Med (2018) 379(1):64–73. doi: 10.1056/NEJMra1706169
12
AdliM. The CRISPR tool kit for genome editing and beyond. Nat Commun (2018) 9(1):1911. doi: 10.1038/s41467-018-04252-2
13
DullTZuffereyRKellyMMandelRJNguyenMTronoDet al. A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 72(11):8463–71. doi: 10.1128/JVI.72.11.8463-8471.1998
14
TsangJY-STanriverYJiangSXueS-ARatnasothyKChenDet al. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest (2008) 118(11):3619–28. doi: 10.1172/JCI33185
15
BoardmanDAPhilippeosCFruhwirthGOIbrahimMAHannenRFCooperDet al. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am J Transplant (2017) 17(4):931–43. 2016/12/28 Ed doi: 10.1111/ajt.14185
16
NoyanFZimmermannKHardtke-WolenskiMKnoefelASchuldeEGeffersRet al. Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor. Am J Transplant (2017) 17(4):917–30. doi: 10.1111/ajt.14175
17
PieriniAIliopoulouBPPeirisHPérez-CruzMBakerJHsuKet al. T cells expressing chimeric antigen receptor promote immune tolerance. JCI Insight (2017) 2(20):e92865. doi: 10.1172/jci.insight.92865
18
BoroughsACLarsonRCChoiBDBouffardAARileyLSSchiferleEet al. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight (2019) 5(8):e126194. doi: 10.1172/jci.insight.126194
19
HonakerYHubbardNXiangYFisherLHaginDSommerKet al. Gene editing to induce FOXP3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function. Sci Transl Med (2020) 12(546). doi: 10.1126/scitranslmed.aay6422
20
SengAKrauszKLPeiDKoestlerDCFischerRTYankeeTMet al. Coexpression of FOXP3 and a Helios isoform enhances the effectiveness of human engineered regulatory T cells. Blood Adv (2020) 4(7):1325–39. doi: 10.1182/bloodadvances.2019000965
21
DawsonNAJRosado-SánchezINovakovskyGEFungVCWHuangQMcIverEet al. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. Sci Transl Med (2020) 12(557). doi: 10.1126/scitranslmed.aaz3866
22
CaoJChenCZengLLiLLiZXuK. Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation. Leukemia Res (2010) 34(10):1374–82. doi: 10.1016/j.leukres.2009.11.024
23
KimYCZhangAHSuYRiederSARossiRJEttingerRAet al. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood (2015) 125(7):1107–15. doi: 10.1182/blood-2014-04-566786
24
YoonJSchmidtAZhangAHKonigsCKimYCScottDW. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. Blood (2017) 129(2):238–45. doi: 10.1182/blood-2016-07-727834
25
HerzogRWKuteyevaVSaboungiRTerhorstCBiswasM. Reprogrammed CD4+ T Cells That Express FoxP3+ Control Inhibitory Antibody Formation in Hemophilia A Mice. Front Immunol (2019) 10:274. doi: 10.3389/fimmu.2019.00274
26
PasseriniLRossi MelESartiranaCFousteriGBondanzaANaldiniLet al. CD4+ T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer. Sci Transl Med (2013) 5(215):215ra174. doi: 10.1126/scitranslmed.3007320
27
GoodwinMLeeELakshmananUShippSFroesslLBarzaghiFet al. CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells. Sci Adv (2020) 6(19):eaaz0571. doi: 10.1126/sciadv.aaz0571
28
AbdeladhimMZhangAHKroppLELindroseARVenkateshaSHMitreEet al. Engineered ovalbumin-expressing regulatory T cells protect against anaphylaxis in ovalbumin-sensitized mice. Clin Immunol (2019) 207:49–54. doi: 10.1016/j.clim.2019.07.009
29
HoriSNomuraTSakaguchiS. Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 299(5609):1057–61. doi: 10.1126/science.1079490
30
ElinavEAdamNWaksTEshharZ. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology (2009) 136(5):1721–31. doi: 10.1053/j.gastro.2009.01.049
31
BlatDZigmondEAlteberZWaksTEshharZ. Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells. Mol Ther (2014) 22(5):1018–28. doi: 10.1038/mt.2014.41
32
SomeyaKNakatsukasaHItoMKondoTTatedaK-IAkanumaTet al. Improvement of Foxp3 stability through CNS2 demethylation by TET enzyme induction and activation. Int Immunol (2017) 29(8):365–75. doi: 10.1093/intimm/dxx049
33
JaeckelEvon BoehmerHMannsMP. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes (2005) 54(2):306–10. doi: 10.2337/diabetes.54.2.306
34
TenspoldeMZimmermannKWeberLCHapkeMLieberMDywickiJet al. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun (2019) 103. doi: 10.1016/j.jaut.2019.05.017
35
FranssonMPirasEBurmanJNilssonBEssandMLuBet al. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation. (2012) 9:112. doi: 10.1186/1742-2094-9-112
36
MalviyaMSaoudiABauerJFillatreauSLiblauR. Treatment of experimental autoimmune encephalomyelitis with engineered bi-specific Foxp3+ regulatory CD4+ T cells. J Autoimmun (2020) 108:102401. doi: 10.1016/j.jaut.2020.102401
37
KimYCZhangAHYoonJCulpWELeesJRWucherpfennigKWet al. Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells. J Autoimmun 2018/06/03 Ed (2018) 92:77–86. doi: 10.1016/j.jaut.2018.05.003
38
FujioKOkamotoAArakiYShodaHTaharaHTsunoNHet al. Gene Therapy of Arthritis with TCR Isolated from the Inflamed Paw. J Immunol (2006) 177(11):8140. doi: 10.4049/jimmunol.177.11.8140
39
AndersenKGButcherTBetzAG. Specific immunosuppression with inducible Foxp3-transduced polyclonal T cells. PloS Biol (2008) 116(11):e276. doi: 10.1371/journal.pbio.0060276
40
WrightGPNotleyCAXueS-ABendleGMHollerASchumacherTNet al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci USA (2009) 106(45):19078–83. doi: 10.1073/pnas.0907396106
41
QianZLathamKAWhittingtonKBMillerDCBrandDDRosloniecEF. Engineered regulatory T cells coexpressing MHC class II:peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis. J Immunol (2013) 190(11):5382–91. doi: 10.4049/jimmunol.1300024
42
KansalRRichardsonNNeeliIKhawajaSChamberlainDGhaniMet al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med (2019) 11(482). doi: 10.1126/scitranslmed.aav1648
43
LoserKHansenWApeltJBalkowSBuerJBeissertS. In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. Gene Ther (2005) 12(17):1294–304. doi: 10.1038/sj.gt.3302567
44
EllebrechtCTBhojVGNaceAChoiEJMaoXChoMJet al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science (2016) 353(6295):179–84. doi: 10.1126/science.aaf6756
45
ZhouQUhligKMMuthAKimpelJLévyCMünchRCet al. Exclusive Transduction of Human CD4 + T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors. JI (2015) 195(5):2493–501. doi: 10.4049/jimmunol.1500956
46
IvicsZHackettPBPlasterkRHIzsvákZ. Molecular Reconstruction of Sleeping Beauty, a Tc1-like Transposon from Fish, and Its Transposition in Human Cells. Cell (1997) 91(4):501–10. doi: 10.1016/S0092-8674(00)80436-5
47
HuangXWilberACBaoLTuongDTolarJOrchardPJet al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood (2006) 107(2):483–91. doi: 10.1182/blood-2005-05-2133
48
Hacein-Bey-AbinaS. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. Science (2003) 302(5644):415–9. doi: 10.1126/science.1088547
49
SchollerJBradyTLBinder-SchollGHwangW-TPlesaGHegeKMet al. Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells. Sci Trans Med (2012) 4(132):132ra53–132ra53. doi: 10.1126/scitranslmed.3003761
50
MarcucciKTJadlowskyJKHwangW-TSuhoski-DavisMGonzalezVEKulikovskayaIet al. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Mol Ther (2018) 26(1):269–79. doi: 10.1016/j.ymthe.2017.10.012
51
ParkJHRivièreIGonenMWangXSénéchalBCurranKJet al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med (2018) 378(5):449–59. doi: 10.1056/NEJMoa1709919
52
SmithTTStephanSBMoffettHFMcKnightLEJiWReimanDet al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotech (2017) 12(8):813–20. doi: 10.1038/nnano.2017.57
53
MátésLChuahMKLBelayEJerchowBManojNAcosta-SanchezAet al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet (2009) 41(6):753–61. doi: 10.1038/ng.343
54
QuerquesIMadesAZulianiCMiskeyCAlbMGruesoEet al. A highly soluble Sleeping Beauty transposase improves control of gene insertion. Nat Biotechnol (2019) 37(12):1502–12. doi: 10.1038/s41587-019-0291-z
55
ClaussJObenausMMiskeyCIvicsZIzsvákZUckertWet al. Efficient Non-Viral T-Cell Engineering by Sleeping Beauty Minicircles Diminishing DNA Toxicity and miRNAs Silencing the Endogenous T-Cell Receptors. Hum Gene Ther (2018) 29(5):569–84. doi: 10.1089/hum.2017.136
56
PerezEEWangJMillerJCJouvenotYKimKALiuOet al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 26(7):808–16. doi: 10.1038/nbt1410
57
TebasPSteinDTangWWFrankIWangSQLeeGet al. Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med (2014) 370(10):901–10. doi: 10.1056/NEJMoa1300662
58
QasimWZhanHSamarasingheSAdamsSAmroliaPStaffordSet al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med (2017) 9(374):eaaj2013. doi: 10.1126/scitranslmed.aaj2013
59
LalGZhangNvan der TouwWDingYJuWBottingerEPet al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol (2009) 182(1):259–73. doi: 10.4049/jimmunol.182.1.259
60
LiuYWangLHanRBeierUHAkimovaTBhattiTet al. Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3+ T-regulatory cell development and function. Mol Cell Biol (2014) 34(21):3993–4007. doi: 10.1128/MCB.00919-14
61
BeierUHWangLBhattiTRLiuYHanRGeGet al. Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol (2011) 31(5):1022–9. doi: 10.1128/MCB.01206-10
62
WohlfertEAGraingerJRBouladouxNKonkelJEOldenhoveGRibeiroCHet al. GATA3 controls Foxp3+ regulatory T cell fate during inflammation in mice. J Clin Invest (2011) 121(11):4503–15. doi: 10.1172/JCI57456
63
LooC-SGatchalianJLiangYLeblancMXieMHoJet al. A Genome-wide CRISPR Screen Reveals a Role for the Non-canonical Nucleosome-Remodeling BAF Complex in Foxp3 Expression and Regulatory T Cell Function. Immunity202053(1):143–157.e8.
64
QuintanaFJBassoASIglesiasAHKornTFarezMFBettelliEet al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 453(7191):65–71. doi: 10.1038/nature06880
65
DangEVBarbiJYangH-YJinasenaDYuHZhengYet al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 146(5):772–84. doi: 10.1016/j.cell.2011.07.033
66
Overacre-DelgoffeAEChikinaMDadeyREYanoHBrunazziEAShayanGet al. Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity. Cell (2017) 169(6):1130–41.e11. doi: 10.1016/j.cell.2017.05.005
67
SchumannJStankoKWoertgeSAppeltCSchumannMKuhlAAet al. The mitochondrial protein TCAIM regulates activation of T cells and thereby promotes tolerance induction of allogeneic transplants. Am J Transplant 2014/11/05 Ed (2014) 14(12):2723–35. doi: 10.1111/ajt.12941
68
DurandMDuboisFDejouCDurandEDangerRChesneauMet al. Increased degradation of ATP is driven by memory regulatory T cells in kidney transplantation tolerance. Kidney Int (2018) 93(5):1154–64. doi: 10.1016/j.kint.2017.12.004
69
Álvarez-SánchezNCruz-ChamorroIDíaz-SánchezMLardonePJGuerreroJMCarrillo-VicoA. Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients. Sci Rep (2019) 9(1):2302. doi: 10.1038/s41598-019-38897-w
70
WangXChangW-CWongCWColcherDShermanMOstbergJRet al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood (2011) 118(5):1255–63. doi: 10.1182/blood-2011-02-337360
71
PhilipBKokalakiEMekkaouiLThomasSStraathofKFlutterBet al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood (2014) 124(8):1277–87. doi: 10.1182/blood-2014-01-545020
72
MestermannKGiavridisTWeberJRydzekJFrenzSNerreterTet al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med (2019) 11(499). doi: 10.1126/scitranslmed.aau5907
73
KinoshitaMKayamaHKusuTYamaguchiTKunisawaJKiyonoHet al. Dietary folic acid promotes survival of Foxp3+ regulatory T cells in the colon. J Immunol (2012) 189(6):2869–78. doi: 10.4049/jimmunol.1200420
74
KimYGChaJChandrasegaranS. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci (1996) 93(3):1156–60. doi: 10.1073/pnas.93.3.1156
75
PorteusMH. Chimeric Nucleases Stimulate Gene Targeting in Human Cells. Science (2003) 300(5620):763–3. doi: 10.1126/science.1078395
76
UrnovFDMillerJCLeeY-LBeausejourCMRockJMAugustusSet al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 435(7042):646–51. doi: 10.1038/nature03556
77
NishimasuHShiXIshiguroSGaoLHiranoSOkazakiSet al. Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science (2018) 361(6408):1259–62. doi: 10.1126/science.aas9129
78
HuangTPZhaoKTMillerSMGaudelliNMOakesBLFellmannCet al. Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors. Nat Biotechnol (2019) 37(6):626–31. doi: 10.1038/s41587-019-0134-y
79
WaltonRTChristieKAWhittakerMNKleinstiverBP. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science (2020) 368(6488):290–6. doi: 10.1126/science.aba8853
80
RothTLPuig-SausCYuRShifrutECarnevaleJLiPJet al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature (2018) 559(7714):405–9. doi: 10.1038/s41586-018-0326-5
81
CortezJTMontautiEShifrutEGatchalianJZhangYShakedOet al. CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature2020582(7812):416–20. doi: 10.1038/s41586-020-2246-4.
82
BroedersMHerrero-HernandezPErnstMPTvan der PloegATPijnappelWWMP. Sharpening the Molecular Scissors: Advances in Gene-Editing Technology. iScience (2020) 23(1):100789. doi: 10.1016/j.isci.2019.100789
83
ReesHALiuDR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet (2018) 19(12):770–88. doi: 10.1038/s41576-018-0059-1
84
WebberBRLonetreeCKluesnerMGJohnsonMJPomeroyEJDiersMDet al. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun (2019) 10(1):5222. doi: 10.1038/s41467-019-13778-y
85
AnzaloneAVRandolphPBDavisJRSousaAAKoblanLWLevyJMet al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature (2019) 576(7785):149–57. doi: 10.1038/s41586-019-1711-4
86
BakROPorteusMH. CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors. Cell Reports (2017) 20(3):750–6. doi: 10.1016/j.celrep.2017.06.064
87
IbraheimRSongC-QMirAAmraniNXueWSontheimerEJ. All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. Genome Biol (2018) 19(1):137. doi: 10.1186/s13059-018-1515-0
88
KroossSADaiZSchmidtFRovaiAFakhiriJDhingraAet al. Ex Vivo/In vivo Gene Editing in Hepatocytes Using “All-in-One” CRISPR-Adeno-Associated Virus Vectors with a Self-Linearizing Repair Template. iScience (2020) 23(1):100764. doi: 10.1016/j.isci.2019.100764
89
OrtinskiPIO’DonovanBDongXKantorB. Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing. Mol Ther - Methods Clin Dev (2017) 5:153–64. doi: 10.1016/j.omtm.2017.04.002
90
LyuPJavidi-ParsijaniPAtalaALuB. Delivering Cas9/sgRNA ribonucleoprotein (RNP) by lentiviral capsid-based bionanoparticles for efficient ‘hit-and-run’ genome editing. Nucleic Acids Res (2019) 47(17):e99–9. doi: 10.1093/nar/gkz605
91
LeeCMCradickTJFineEJBaoG. Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off-target Effects in Genome Editing. Mol Ther (2016) 24(3):475–87. doi: 10.1038/mt.2016.1
92
KosickiMTombergKBradleyA. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol (2018) 36(8):765–71. doi: 10.1038/nbt.4192
93
CullotGBoutinJToutainJPratFPennamenPRooryckCet al. CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. Nat Commun (2019) 10(1):1136. doi: 10.1038/s41467-019-09006-2
94
RenJZhangXLiuXFangCJiangSJuneCHet al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget (2017) 8(10):17002–11. doi: 10.18632/oncotarget.15218
95
StadtmauerEAFraiettaJADavisMMCohenADWeberKLLancasterEet al. CRISPR-engineered T cells in patients with refractory cancer. Science (2020) 367(6481):eaba7365. doi: 10.1126/science.aba7365
96
GorovitsBKorenE. Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics. BioDrugs (2019) 33(3):275–84. doi: 10.1007/s40259-019-00354-5
97
HegeKMBergslandEKFisherGANemunaitisJJWarrenRSMcArthurJGet al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunotherapy cancer (2017) 5(1):22. doi: 10.1186/s40425-017-0222-9
98
WagnerDLAminiLWenderingDJBurkhardtL-MAkyüzLReinkePet al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med (2019) 25(2):242–8. doi: 10.1038/s41591-018-0204-6
99
HoffmannPBoeldTJEderRHuehnJFloessSWieczorekGet al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol (2009) 39(4):1088–97. doi: 10.1002/eji.200838904
100
ZhouXBailey-BucktroutSLJekerLTPenarandaCMartínez-LlordellaMAshbyMet al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 10(9):1000–7. doi: 10.1038/ni.1774
101
BeavisPAGregoryBGreenPCribbsAPKennedyAAmjadiPet al. Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proc Natl Acad Sci USA (2011) 108(40):16717–22. doi: 10.1073/pnas.1112722108
102
AllanSEAlstadANMerindolNCrellinNKAmendolaMBacchettaRet al. Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther (2008) 16(1):194–202. doi: 10.1038/sj.mt.6300341
103
Aarts-RiemensTEmmelotMEVerdonckLFMutisT. Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells. Eur J Immunol (2008) 38(5):1381–90. doi: 10.1002/eji.200737590
104
ForstneričVOvenIOgorevcJLainščekDPraznikALebarTet al. CRISPRa-mediated FOXP3 gene upregulation in mammalian cells. Cell Biosci (2019) 9:93. doi: 10.1186/s13578-019-0357-0
105
KimH-PLeonardWJ. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med (2007) 204(7):1543–51. doi: 10.1084/jem.20070109
106
JansonPCJWinerdalMEMaritsPThörnMOhlssonRWinqvistO. FOXP3 promoter demethylation reveals the committed Treg population in humans. PloS One (2008) 3(2):e1612. doi: 10.1371/journal.pone.0001612
107
PolanskyJKKretschmerKFreyerJFloessSGarbeABaronUet al. DNA methylation controls Foxp3 gene expression. Eur J Immunol (2008) 38(6):1654–63. doi: 10.1002/eji.200838105
108
OkadaMKanamoriMSomeyaKNakatsukasaHYoshimuraA. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells. Epigenet Chromatin (2017) 10:24. doi: 10.1186/s13072-017-0129-1
109
TaoRde ZoetenEFOzkaynakEWangLLiBGreeneMIet al. Histone deacetylase inhibitors and transplantation. Curr Opin Immunol (2007) 19(5):589–95. doi: 10.1016/j.coi.2007.07.015
110
TaoRde ZoetenEFOzkaynakEChenCWangLPorrettPMet al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med (2007) 13(11):1299–307. doi: 10.1038/nm1652
111
SamantaALiBSongXBembasKZhangGKatsumataMet al. TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci USA (2008) 105(37):14023–7. doi: 10.1073/pnas.0806726105
112
van LoosdregtJVercoulenYGuichelaarTGentYYJBeekmanJMvan BeekumOet al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood (2010) 115(5):965–74. doi: 10.1182/blood-2009-02-207118
113
XiaoYLiBZhouZHancockWWZhangHGreeneMI. Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Curr Opin Immunol (2010) 22(5):583–91. doi: 10.1016/j.coi.2010.08.013
114
ChenZBarbiJBuSYangH-YLiZGaoYet al. The ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by promoting degradation of the transcription factor Foxp3. Immunity (2013) 39(2):272–85. doi: 10.1016/j.immuni.2013.08.006
115
NiXKouWGuJWeiPWuXPengHet al. TRAF6 directs FOXP3 localization and facilitates regulatory T-cell function through K63-linked ubiquitination. EMBO J (2019) 38(9). doi: 10.15252/embj.201899766
116
XuYMelo-CardenasJZhangYGauIWeiJMontautiEet al. The E3 ligase Hrd1 stabilizes Tregs by antagonizing inflammatory cytokine-induced ER stress response. JCI Insight (2019) 4(5). doi: 10.1172/jci.insight.121887
117
DengGNagaiYXiaoYLiZDaiSOhtaniTet al. Pim-2 Kinase Influences Regulatory T Cell Function and Stability by Mediating Foxp3 Protein N-terminal Phosphorylation. J Biol Chem (2015) 290(33):20211–20. doi: 10.1074/jbc.M115.638221
118
MorawskiPAMehraPChenCBhattiTWellsAD. Foxp3 protein stability is regulated by cyclin-dependent kinase 2. J Biol Chem (2013) 288(34):24494–502. doi: 10.1074/jbc.M113.467704
119
SemenzaGL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE (2007) 2007(407):cm8. doi: 10.1126/stke.4072007cm8
120
NakamuraHMakinoYOkamotoKPoellingerLOhnumaKMorimotoCet al. TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J Immunol (2005) 174(12):7592–9. doi: 10.4049/jimmunol.174.12.7592
121
ShehadeHAcoltyVMoserMOldenhoveG. Cutting Edge: Hypoxia-Inducible Factor 1 Negatively Regulates Th1 Function. J Immunol (2015) 195(4):1372–6. doi: 10.4049/jimmunol.1402552
122
LeeJHEllyCParkYLiuY-C. E3 ubiquitin ligase VHL regulates hypoxia-inducible factor-1α to maintain regulatory T cell stability and suppressive capacity. Immunity (2015) 42(6):1062–74.
123
ShiLZWangRHuangGVogelPNealeGGreenDRet al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 208(7):1367–76. doi: 10.1084/jem.20110278
124
FeldhoffLMRuedaCMMoreno-FernandezMESauerJJacksonCMChougnetCAet al. IL-1β induced HIF-1α inhibits the differentiation of human FOXP3+ T cells. Sci Rep (2017) 7(1):465.
125
Ben-ShoshanJSchwartzSLuboshitsGMaysel-AuslenderSBarzelayAPolak-CharconSet al. Constitutive expression of HIF-1alpha and HIF-2alpha in bone marrow stromal cells differentially promotes their proangiogenic properties. Stem Cells Dayt Ohio (2008) 26(10):2634–43.
126
ClambeyETMcNameeENWestrichJAGloverLECampbellELJedlickaPet al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA (2012) 109(41):E2784–2793.
127
YeJQiuJBostickJWUedaASchjervenHLiSet al. The Aryl Hydrocarbon Receptor Preferentially Marks and Promotes Gut Regulatory T Cells. Cell Rep (2017) 21(8):2277–90. doi: 10.1016/j.celrep.2017.10.114
128
GandhiRKumarDBurnsEJNadeauMDakeBLaroniAet al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol (2010) 11(9):846–53.
129
ZamaliIRekikRBelhadj HmidaNBen HmidAKammounOBarboucheM-Ret al. An endogenous aryl hydrocarbon receptor ligand enhances de novo generation of regulatory T cells in humans. J Leukoc Biol (2019) 105(2):291–5.
130
LiZLinFZhuoCDengGChenZYinSet al. PIM1 kinase phosphorylates the human transcription factor FOXP3 at serine 422 to negatively regulate its activity under inflammation. J Biol Chem (2014) 289(39):26872–81. doi: 10.1074/jbc.M114.586651
131
KornTMitsdoerfferMCroxfordALAwasthiADardalhonVAGalileosGet al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA (2008) 105(47):18460–5. doi: 10.1073/pnas.0809850105
132
FujimotoMSeradaSMiharaMUchiyamaYYoshidaHKoikeNet al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheumatol (2008) 58(12):3710–9. doi: 10.1002/art.24126
133
JonesSASchellerJRose-JohnS. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest (2011) 121(9):3375–83. doi: 10.1172/JCI57158
134
HagensteinJMelderisSNoskoAWarkotschMTRichterJVRamckeTet al. A Novel Role for IL-6 Receptor Classic Signaling: Induction of ROR γ t + Foxp3 + Tregs with Enhanced Suppressive Capacity. JASN (2019) 30(8):1439–53. doi: 10.1681/ASN.2019020118
135
SchenkUFrascoliMProiettiMGeffersRTraggiaiEBuerJet al. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal (2011) 4(162):ra12. doi: 10.1126/scisignal.2001270
136
FigliuoloVRSavioLEBSafyaHNaniniHBernardazziCAbaloAet al. P2X7 receptor promotes intestinal inflammation in chemically induced colitis and triggers death of mucosal regulatory T cells. Biochim Biophys Acta Mol Basis Dis (2017) 1863(6):1183–94. doi: 10.1016/j.bbadis.2017.03.004
137
HuangSApasovSKoshibaMSitkovskyM. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood (1997) 90(4):1600–10. doi: 10.1182/blood.V90.4.1600
138
OhtaAKiniROhtaASubramanianMMadasuMSitkovskyM. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol (2012) 3:190. doi: 10.3389/fimmu.2012.00190
139
SaraivaMVieiraPO’GarraA. Biology and therapeutic potential of interleukin-10. J Exp Med (2020) 217(1). doi: 10.1084/jem.20190418
140
LevingsMKSangregorioRSartiranaCMoschinALBattagliaMOrbanPCet al. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med (2002) 196(10):1335–46. doi: 10.1084/jem.20021139
141
BézieSPicardaEOssartJTessonLUsalCRenaudinKet al. IL-34 is a Treg-specific cytokine and mediates transplant tolerance. J Clin Invest (2015) 125(10):3952–64. doi: 10.1172/JCI81227
142
GuillonneauCBézieSAnegonI. Immunoregulatory properties of the cytokine IL-34. Cell Mol Life Sci (2017) 74(14):2569–86. doi: 10.1007/s00018-017-2482-4
143
SawantDVHamiltonKVignaliDAA. Interleukin-35: Expanding Its Job Profile. J Interferon Cytokine Res (2015) 35(7):499–512. doi: 10.1089/jir.2015.0015
144
BézieSPicardaETessonLRenaudinKDurandJMénoretSet al. Fibrinogen-Like Protein 2/Fibroleukin Induces Long-Term Allograft Survival in a Rat Model through Regulatory B Cells. Chatenoud L, editor. PloS One (2015) 10(3):e0119686. doi: 10.1371/journal.pone.0119686
145
HuJYanJRaoGLathaKOverwijkWWHeimbergerABet al. The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol (2016) 35(4):325–39. doi: 10.3109/08830185.2014.956360
146
SilvaSLAlbuquerqueASSerra-CaetanoAFoxallRBPiresARMatosoPet al. Human naive regulatory T-cells feature high steady-state turnover and are maintained by IL-7. Oncotarget (2016) 7(11):12163–75. doi: 10.18632/oncotarget.7512
147
FanMYLowJSTanimineNFinnKKPriyadharshiniBGermanaSKet al. Differential Roles of IL-2 Signaling in Developing versus Mature Tregs. Cell Rep (2018) 25(5):1204–13.e4. doi: 10.1016/j.celrep.2018.10.002
148
WhangboJSKimHTNikiforowSKorethJAlhoACFalaheeBet al. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv (2019) 3(7):984–94. doi: 10.1182/bloodadvances.2018027474
149
KhoryatiLKumariSNguyet PhamTMBogdaniMGavinM. Selectively Agonizing Treg in Type 1 Diabetes with IL-2 Muteins. Diabetes (2018) 67(Supplement 1). doi: 10.2337/db18-314-OR
150
PasseriniLAllanSEBattagliaMDi NunzioSAlstadANLevingsMKet al. STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells. Int Immunol (2008) 20(3):421–31. doi: 10.1093/intimm/dxn002
151
SockoloskyJTTrottaEParisiGPictonLSuLLLeACet al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science (2018) 359(6379):1037–42. doi: 10.1126/science.aar3246
152
ShumTOmerBTashiroHKruseRLWagnerDLParikhKet al. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discovery (2017) 7(11):1238–47. doi: 10.1158/2159-8290.CD-17-0538
153
LeenAMSukumaranSWatanabeNMohammedSKeirnanJYanagisawaRet al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther (2014) 22(6):1211–20. doi: 10.1038/mt.2014.47
154
AsanoTMeguriYYoshiokaTKishiYIwamotoMNakamuraMet al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood (2017) 129(15):2186–97. doi: 10.1182/blood-2016-09-741629
155
LiQWangYLiHShenGHuS. Ox-LDL influences peripheral Th17/Treg balance by modulating Treg apoptosis and Th17 proliferation in atherosclerotic cerebral infarction. Cell Physiol Biochem (2014) 33(6):1849–62. doi: 10.1159/000362963
156
TanCLKuchrooJRSagePTLiangDFranciscoLMBuckJet al. PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J Exp Med (2021) 218(1).
157
DongHStromeSESalomaoDRTamuraHHiranoFFliesDBet al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 8(8):793–800. doi: 10.1038/nm730
158
GototJDhanaEYagitaHKaiserRLudwig-PortugallIKurtsC. Antigen-specific Helios(-) , Neuropilin-1(-) Tregs induce apoptosis of autoreactive B cells via PD-L1. Immunol Cell Biol (2018) 96(8):852–62. doi: 10.1111/imcb.12053
159
CharbonnierL-MJanssenEChouJOhsumiTKKelesSHsuJTet al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked–like disorder caused by loss-of-function mutations in LRBA. J Allergy Clin Immunol (2015) 135(1):217–27.e9. doi: 10.1016/j.jaci.2014.10.019
160
LoBZhangKLuWZhengLZhangQKanellopoulouCet al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science (2015) 349(6246):436–40. doi: 10.1126/science.aaa1663
161
HowieDCobboldSPAdamsETen BokumANeculaASZhangWet al. Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight (2017) 2(3):e89160. doi: 10.1172/jci.insight.89160
162
MichalekRDGerrietsVAJacobsSRMacintyreANMacIverNJMasonEFet al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol (2011) 186(6):3299–303. doi: 10.4049/jimmunol.1003613
163
BerodLFriedrichCNandanAFreitagJHagemannSHarmrolfsKet al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med (2014) 20(11):1327–33. doi: 10.1038/nm.3704
164
TimilshinaMYouZLacherSMAcharyaSJiangLKangYet al. Activation of Mevalonate Pathway via LKB1 Is Essential for Stability of Treg Cells. Cell Rep (2019) 27(10):2948–61. doi: 10.1016/j.celrep.2019.05.020
165
SuXWangQGuoWPeiXNiuQLiuMet al. Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation. Cell Mol Immunol (2020) 17(5):483–95. doi: 10.1038/s41423-019-0312-3
166
AngelinAGil-de-GomezLDahiyaSJiaoJGuoLLevineMHet al. Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metab (2017) 25(6):1282–93.e7. doi: 10.1016/j.cmet.2016.12.018
167
HeNFanWHenriquezBYuRTAtkinsARLiddleCet al. Metabolic control of regulatory T cell (Treg) survival and function by Lkb1. Proc Natl Acad Sci USA (2017) 114(47):12542–7. doi: 10.1073/pnas.1715363114
168
San SegundoDRuizJCFernandez-FresnedoGIzquierdoMGomez-AlamilloCCachoEet al. Calcineurin inhibitors affect circulating regulatory T cells in stable renal transplant recipients. Transplant Proc 2006/11/14 Ed (2006) 38(8):2391–3. doi: 10.1016/j.transproceed.2006.08.081
169
De AngelisBDottiGQuintarelliCHuyeLEZhangLZhangMet al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood (2009) 114(23):4784–91. doi: 10.1182/blood-2009-07-230482
170
AminiLWagnerDLRösslerUZarrinradGWagnerLFVollmerTet al. CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients. Mol Ther (2021) 29(1):32–46. doi: 10.1016/j.ymthe.2020.09.011
171
BasarRDaherMUpretyNGokdemirEAlsulimanAEnsleyEet al. Large-scale GMP-compliant CRISPR-Cas9–mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Adv (2020) 4(14):3357–67. doi: 10.1182/bloodadvances.2020001977
172
KaeuferleTDeisenbergerLJablonowskiLStiefTABlaeschkeFWillierSet al. CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation. Mol Ther (2020) 28(9):1965–73. doi: 10.1016/j.ymthe.2020.06.002
173
BrewinJMancaoCStraathofKKarlssonHSamarasingheSAmroliaPJet al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood (2009) 114(23):4792–803. doi: 10.1182/blood-2009-07-228387
174
MahicMHenjumKYaqubSBjørnbethBATorgersenKMTaskénKet al. Generation of highly suppressive adaptive CD8+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation. Eur J Immunol (2008) 38(3):640–6. doi: 10.1002/eji.200737529
175
ZhengJLiuYQinGChanP-LMaoHLamK-Tet al. Efficient Induction and Expansion of Human Alloantigen-Specific CD8 Regulatory T Cells from Naive Precursors by CD40-Activated B Cells. J Immunol (2009) 183(6):3742–50. doi: 10.4049/jimmunol.0901329
176
PicardaEBézieSVenturiVEchasserieauKMérieauEDelhumeauAet al. MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection. J Clin Invest (2014) 124(6):2497–512. doi: 10.1172/JCI71533
177
PicardaEBézieSUseroLOssartJBesnardMHalimHet al. Cross-Reactive Donor-Specific CD8+ Tregs Efficiently Prevent Transplant Rejection. Cell Reports (2019) 29(13):4245–55.e6. doi: 10.1016/j.celrep.2019.11.106
178
TangQHenriksenKJBiMFingerEBSzotGYeJet al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med (2004) 199(11):1455–65. doi: 10.1084/jem.20040139
179
BézieSMeistermannDBoucaultLKilensSZoppiJAutrusseauEet al. Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/– Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice. Front Immunol (2018) 8:2014. doi: 10.3389/fimmu.2017.02014
180
AdairPRKimYCZhangA-HYoonJScottDW. Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision. Front Immunol (2017) 8:1117. doi: 10.3389/fimmu.2017.01117
181
GrossGWaksTEshharZ. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci (1989) 86(24):10024–8. doi: 10.1073/pnas.86.24.10024
182
YehW-ISeayHRNewbyBPosgaiALMonizFBMichelsAet al. Avidity and Bystander Suppressive Capacity of Human Regulatory T Cells Expressing De Novo Autoreactive T-Cell Receptors in Type 1 Diabetes. Front Immunol (2017) 8:1313. doi: 10.3389/fimmu.2017.01313
183
BrockerTRiedingerMKarjalainenK. Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor. Eur J Immunol (1996) 26(8):1770–4. doi: 10.1002/eji.1830260816
184
ProvasiEGenovesePLombardoAMagnaniZLiuP-QReikAet al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med (2012) 18(5):807–15. doi: 10.1038/nm.2700
185
HullCMNickolayLEEstorninhoMRichardsonMWRileyJLPeakmanMet al. Generation of human islet-specific regulatory T cells by TCR gene transfer. J Autoimmun (2017) 79:63–73. doi: 10.1016/j.jaut.2017.01.001
186
PlesaGZhengLMedvecAWilsonCBRobles-OteizaCLiddyNet al. TCR affinity and specificity requirements for human regulatory T-cell function. Blood (2012) 119(15):3420–30. doi: 10.1182/blood-2011-09-377051
187
BeringerDXKleijwegtFSWiedeFvan der SlikARLohKLPetersenJet al. T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex. Nat Immunol (2015) 16(11):1153–61. doi: 10.1038/ni.3271
188
LiuXJiangSFangCYangSOlalereDPequignotECet al. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res (2015) 75(17):3596–607. doi: 10.1158/0008-5472.CAN-15-0159
189
CarusoHGHurtonLVNajjarARushworthDAngSOlivaresSet al. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res (2015) 75(17):3505–18. doi: 10.1158/0008-5472.CAN-15-0139
190
TurtleCJHanafiL-ABergerCGooleyTACherianSHudecekMet al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest (2016) 126(6):2123–38.
191
MausMVHaasARBeattyGLAlbeldaSMLevineBLLiuXet al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res (2013) 1:26–31.
192
AkatsukaY. TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens. Front Immunol (2020) 11:257. doi: 10.3389/fimmu.2020.00257
193
KoristkaSKeglerABergmannRArndtCFeldmannAAlbertSet al. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. J Autoimmun 2018/03/06 Ed (2018) 90:116–31. doi: 10.1016/j.jaut.2018.02.006
194
GornalusseGGHirataRKFunkSERiolobosLLopesVSManskeGet al. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. Nat Biotechnol (2017) 35(8):765–72. doi: 10.1038/nbt.3860
195
DeuseTHuXGravinaAWangDTediashviliGDeCet al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol (2019) 37(3):252–8. doi: 10.1038/s41587-019-0016-3
196
JaiswalSJamiesonCHMPangWWParkCYChaoMPMajetiRet al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell (2009) 138(2):271–85. doi: 10.1016/j.cell.2009.05.046
197
BrunsteinCGMillerJSMcKennaDHHippenKLDeForTESumstadDet al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood (2016) 127(8):1044–51.
198
BrandtLJBBarnkobMBMichaelsYSHeiselbergJBaringtonT. Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review. Front Immunol (2020) 11:326. doi: 10.3389/fimmu.2020.00326
199
TimmermansFVelgheIVanwalleghemLDe SmedtMVan CoppernolleSTaghonTet al. Generation of T cells from human embryonic stem cell-derived hematopoietic zones. J Immunol (2009) 182(11):6879–88. doi: 10.4049/jimmunol.0803670
200
ThemeliMKlossCCCirielloGFedorovVDPernaFGonenMet al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol (2013) 31(10):928–33. doi: 10.1038/nbt.2678
201
BluestoneJABucknerJHFitchMGitelmanSEGuptaSHellersteinMKet al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med (2015) 7(315):315ra189. doi: 10.1126/scitranslmed.aad4134
202
Sharif-PaghalehESunasseeKTavaréRRatnasothyKKoersAAliNet al. In Vivo SPECT Reporter Gene Imaging of Regulatory T Cells. Zimmer J, editor. PloS One (2011) 6(10):e25857. doi: 10.1371/journal.pone.0025857
203
RaffinCZhouYPiccoliLLanzavecchiaASadelainMTareenSUet al. Development of citrullinated-vimentin-specific CAR for targeting Tregs to treat autoimmune rheumatoid arthritis. J Immunol (2018) 200(1 Supplement):176.17.
204
BurzynDKuswantoWKolodinDShadrachJLCerlettiMJangYet al. A Special Population of Regulatory T Cells Potentiates Muscle Repair. Cell (2013) 155(6):1282–95. doi: 10.1016/j.cell.2013.10.054
205
DombrowskiYO’HaganTDittmerMPenalvaRMayoralSRBankheadPet al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat Neurosci (2017) 20(5):674–80. doi: 10.1038/nn.4528
206
NosbaumAPrevelNTruongH-AMehtaPEttingerMScharschmidtTCet al. Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing. JI (2016) 196(5):2010–4. doi: 10.4049/jimmunol.1502139
207
ZacchignaSMartinelliVMoimasSCollivaAAnziniMNordioAet al. Paracrine effect of regulatory T cells promotes cardiomyocyte proliferation during pregnancy and after myocardial infarction. Nat Commun (2018) 9(1):2432. doi: 10.1038/s41467-018-04908-z
208
SchlundtCReinkeSGeisslerSBucherCHGianniniCMärdianSet al. Individual Effector/Regulator T Cell Ratios Impact Bone Regeneration. Front Immunol (2019) 10:1954. doi: 10.3389/fimmu.2019.01954
209
SommermeyerDHudecekMKosasihPLGogishviliTMaloneyDGTurtleCJet al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia (2016) 30(2):492–500. doi: 10.1038/leu.2015.247
210
RoybalKTWilliamsJZMorsutLRuppLJKolinkoIChoeJHet al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell (2016) 167(2):419–432.e16. doi: 10.1016/j.cell.2016.09.011
211
AdigbliGMénoretSCrossARHesterJIssaFAnegonI. Humanization of Immunodeficient Animals for the Modeling of Transplantation, Graft Versus Host Disease and Regenerative Medicine. Transplantation (2020) 104(11):2290–306. doi: 10.1097/TP.0000000000003177
212
MarxUAkabaneTAnderssonTBBakerEBeilmannMBekenSet al. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX (2020) 37(3):365–94. doi: 10.14573/altex.2001241
Summary
Keywords
immune tolerance, transplantation, autoimmunity, genome editing, CAR, cell therapy, immune regulation, regulatory T cells
Citation
Amini L, Greig J, Schmueck-Henneresse M, Volk H-D, Bézie S, Reinke P, Guillonneau C, Wagner DL and Anegon I (2021) Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications. Front. Immunol. 11:611638. doi: 10.3389/fimmu.2020.611638
Received
29 September 2020
Accepted
24 December 2020
Published
24 February 2021
Volume
11 - 2020
Edited by
James Moon, University of Michigan, United States
Reviewed by
Fan Pan, Chinese Academy of Sciences (CAS), China; Hyewon Phee, Amgen, United States
Updates
Copyright
© 2021 Amini, Greig, Schmueck-Henneresse, Volk, Bézie, Reinke, Guillonneau, Wagner and Anegon.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ignacio Anegon, ianegon@nantes.inserm.fr; Dimitrios L. Wagner, Dimitrios-L.Wagner@charite.de; Carole Guillonneau, Carole.Guillonneau@univ-nantes.fr
†These authors have contributed equally to this work
‡These authors share senior authorship
This article was submitted to Immunological Tolerance and Regulation, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.